Cisplatin-based combination chemotherapy has considerably improved the outcome of patients with metastatic germ cell tumours. Around 75-80% of patients are cured by first-line treatment. However, 20-25% of patients develop disease progression during or after their initial chemotherapy and require effective salvage treatment. The prognosis of the latter patient group is relatively poor with only 20-30% disease-free long-term survival (Motzer et al., 1991; Josefsen et al., 1993; Einhorn et al., 1994) .
This retrospective study analyses outcome in patients who received salvage treatment for refractory or relapsing germ cell tumours at a single institution. We (Mead et al., 1992) . Patients with liver, bone, or brain metastases, a mediastinal mass > 5 cm, 20 or more lung metastases, AFP > 1000 IU ml-' and/or HCG >10 000 U 1-' constituted a poor-risk group. Patients without any of these features were considered as good-risk. Patient characteristics pertaining to status immediately before initial chemotherapy are summarised in Table I .
Primary treatment
Up to 1983 all patients received their primary chemotherapy according to the PVB protocol consisting of cisplatin 20mgm-2 on days 1-5, vinblastine 0.15-0.20mgkg-' on days 1,2 and bleomycin 30 mg on days 2, 9, 16 (Einhorn and Donohue, 1977) . Since 1984 patients with a large tumour burden have been predominantly treated according to the ECBC schedule consisting of etoposide 120 mg m 2 on days 1-4, cisplatin 30 mg m2 on days 1-4, bleomycin 15 mg on day 1 (bolus) and 12 mg m2 on days 1-4 (24h infusion), and cyclophosphamide 300 mg m 2 on days 1-4 (Gerl et al., 1993a,b) . In 1987 we began to treat patients with low-volume metastatic disease according to the PEB regimen substituting etoposide 100 mg m2 on days 1-5 for vinblastine (Williams (Einhorn et al., 1989) . All other patients received at least four courses of chemotherapy provided they did not develop progressive disease (PD) earlier during treatment. Patients with largevolume metastatic disease and very high levels of serum tumour markers usually received more than four cycles of chemotherapy (Gerl et al., 1993b) . The relative drug intensity of cisplatin was calculated for an individual patient assuming that 100mg m2 given within 3 weeks represented the standard dose (100%) (Longo et al., 1991) .
Fifty patients had residual masses at the end of primary chemotherapy, 28 (56%) of whom were selected for adjunctive surgery after normalisation of serum tumour markers (Table II) (Table  III) . Since 1984 11 patients have received salvage chemotherapy according to the ECBC schedule (Gerl et al., 1993a,b) . Three patients were treated with other cisplatinbased regimens, and four patients received non-cisplatincontaining protocols. The majority of patients received 3-4 courses of salvage chemotherapy depending on the course of disease and toxicity. Dose reductions were performed as indicated by clinical, haematological or renal toxicity. Four Salvage treatment of germ cell tumours A Gerl et al patients underwent high-dose chemotherapy with autologous bone marrow rescue; two patients received a regimen consisting of etoposide and cyclophosphamide, while the other two patients were treated with carboplatin-based protocols.
Seven patients did not receive any salvage chemotherapy. One patient with Friedreich's ataxia who relapsed with a retroperitoneal mass and increasing AFP 3 years after discontinuation of primary treatment was successfully salvaged by surgery alone. Six patients who had an isolated cerebral relapse were treated by surgery and subsequent whole brain irradiation or radiotherapy alone (one patient) (Gerl et al., 1994) .
Overall 35 patients underwent surgery at some stage during their salvage treatment. Retroperitoneal lymph node dissection (RPLND) was performed in 21 patients, thoracotomy in seven and craniotomy in eight. Fourteen of these 35 patients (40%) had already undergone surgical interventions as part of their primary treatment. In patients with marker negative relapses surgery was routinely undertaken as first salvage treatment in order to recognise disease reactivation with mature teratoma only. Furthermore, some heavily pretreated patients with localised disease that was deemed resectable were referred to surgery as first salvage modality.
Of 60 patients 42 (70%) had residual masses after salvage (second-line) chemotherapy. Nine of these 42 patients (21%) were referred to surgery. Five of these nine patients had normal tumour markers and three of them harboured viable cancer; the remaining four patients had elevated tumour markers and all harboured viable cancer.
Overall 15 patients who had chemorefractory disease or who relapsed after at least two chemotherapy regimens underwent surgical salvage as defined elsewhere (Murphy et al., 1993) . Eleven of these 15 patients underwent RPLND as salvage surgery, four patients thoracotomy; serum HCG was elevated in eight patients before salvage surgery, AFP in seven.
Twenty-seven patients underwent radiotherapy as part of their salvage treatment, most often given with palliative intention. Of the 27 patients 18 had whole-brain irradiation for cerebral metastases. 
Survival
Overall survival from the beginning of salvage treatment is shown in Figure 1 . At the end of the observation time 20 patients (30%) are alive with NED status, 15 continuously disease free after second-line treatment and five after further treatment. Four additional patients are alive with disease and currently receive third-line treatment. Forty-three patients died with a median of 9 months after start of salvage treatment. Of these 43 patients 40 died within 2 years, whereas three patients survived for 65, 91 and 107 months respectively.
Of the pretreatment factors age < 35 years, testicular origin and low-volume metastatic disease as defined by three different staging systems were associated with favourable long-term outcome (Table IV) . In contrast, the use of vinblastine-or etoposide-containing regimens and the relative drug intensity of cisplatin did not affect outcome. However, a CR to primary treatment and a relapse-free interval > 3 months predicted a favourable prognosis after salvage treatment. Low-volume metastatic disease and absence of pulmonary metastases at start of salvage treatment were also associated with favourable long-term outcome. Serum tumour marker status before salvage treatment was not of prognostic relevance.
Multivariate analysis identified age < 35 years, CR to primary treatment and a relapse-free interval >3 months as independent predictors of favourable outcome (Table V) . These factors were used to define a simple prognostic model. Patients with only good-risk factors (n = 28, 42%) had a 5 year survival of 72% (95% confidence interval 54-90%), whereas patients with at least one poor-risk factor (n = 39, 58%) (age >35 years, <CR2 to primary treatment, relapsefree interval < 3 months) had a 5 year survival of only 1 1% (95% CI 0-22%) (Figure 2 Figure 1 Survival from the beginning of salvage treatment for 67 patients relapsing during or after primary therapy. Eighteen patients remain at risk at 60 months. chemotherapy . Similar CR rates can be achieved with other salvage regimens (Ledermann et al., 1994) . Unfortunately, about one-half of the patients with CR to second-line chemotherapy relapse again resulting in Time (months) Figure 2 Survival from the beginning of salvage treatment by prognostic group: good prognosis (n = 28, 42%), no poor-risk factor (----); poor prognosis (n = 39, 58%), at least one poor-risk factor (age>35 years, incomplete response to primary therapy, relapse-free interval < 3 months).
disease-free long-term survival between 20% and 30% (Harstrick et al., 1991; Motzer et al., 1991; Josefsen et al., 1993; Einhorn et al., 1994) . The 30% disease-free survival rate at a median follow-up of 90 months observed in our study is thus comparable to the results of other authors and stresses the need for continued investigation of potentially more efficacious salvage treatment.
Apart from second-line chemotherapy surgery plays an important role as part of salvage treatment. In patients with marker negative relapses surgery should be the first salvage procedure to recognise regrowth with mature teratoma which is adequately treated by surgery alone (Jansen et al., 1991) . Differential diagnosis of marker negative relapse also includes second malignancy as observed in one of our patients who developed a glioblastoma more than 9 years after whole-brain irradiation for cerebral metastases. Patients with normal tumour markers but residual masses after second-line chemotherapy should undergo resection whenever feasible, as the chance of harbouring viable cancer is over 50% (Fox et al., 1993) . Moreover, surgery has a small but definite curative potential in chemorefractory resectable disease (Cassidy et al., 1992; Murphy et al., 1993) . Three of 15 patients (20%) with this condition were disease-free longterm survivors in our study. Patients with a single cerebral metastasis and no evidence of disease at other sites underwent surgical removal and subsequent whole brain irradiat- ion. Three of six patients with this condition survived disease free (Gerl et al., 1994) .
To overcome drug resistance high-dose chemotherapy with autologous bone marrow or peripheral stem cell rescue has been evaluated by several investigators. However, using highdose chemotherapy as third-line treatment clinical outcome is disappointing with only 15-20% long-term disease-free survival Siegert et al., 1994) . More encouraging results have been reported for patients treated with high-dose chemotherapy at an earlier stage (Barnett et al., 1993; Broun et al., 1994; Siegert et al., 1994) . However, at present there is no consensus about inclusion criteria. If all patients with poor-risk features as defined by the largest prognostic factor analysis (Mead et al., 1992) were selected for high-dose chemotherapy as first-line treatment, approximately two-thirds of patients would receive a toxic and costly overtreatment. Whereas one group of investigators used a prolonged serum tumour marker decline during the first two courses of primary chemotherapy as selection criterion for early intervention with high-dose chemotherapy (Motzer et al., 1992) , two recent reports could not substantiate the prognostic importance of early serum tumour marker half-life (Gerl et al., 1993a; Stevens et al., 1995) . Therefore, search for appropriate treatment-related variables which complement pretreatment risk stratification has to be continued.
Looking at pretreatment prognostic variables in our study, age > 35 years, extragonadal origin and large-volume metastatic disease as defined by three different staging systems predicted poor prognosis after salvage treatment. The last two parameters were identified by other investigators (Motzer et al., 1991; Droz et al., 1993; Saxman et al., 1994) , but these variables lost their prognostic relevance in our multivariate model. Although age has been identified as a prognostic factor in two studies including large numbers of patients with non-seminomatous germ cell tumours (Aass et al., 1991; Mead et al., 1992) , its relevance in predicting outcome of salvage treatment has not been reported previously.
In agreement with other reports a CR to primary treatment was identified as most important predictor of favourable outcome of salvage treatment (Harstrick et al., 1991; Motzer et al., 1991; Pizzocaro et al., 1992; Droz et al., 1993) . As described by several investigators the prognostic relevance of the relapse-free interval was substantiated by our study (Horwich et al., 1993; Josefsen et al., 1993; Steyerberg et al., 1993; Gerl et al., 1995) , although it reached only borderline significance in our multivariate model.
As in previous reports tumour burden at start of salvage treatment was correlated to long-term outcome (Loehrer et al., 1988; Motzer et al., 1991; Horwich et al., 1993) . Patients with marker elevation only or one site of disease fared markedly better than patients with two or more sites of metastatic spread. In concordance with other investigators we found that presence of pulmonary metastases at start of salvage treatment was an adverse prognostic factor (Droz et al., 1993) .
Multivariate analysis identified age <35 years, CR to primary treatment and a relapse-free period of more than 3 months as independent prognostic variables predictive of favourable outcome of salvage treatment. These prognostic factors allowed us to define a subgroup of patients who fared relatively well with conventional salvage treatment as shown by a 5 year survival rate of 72%. The remaining patients had a 5 year survival of only 11%. The division into good and poor prognostic groups is easily applied. However, as our study included only 67 patients, the general applicability of the results is limited to a certain degree (Simon and Altman, 1994) . The validity of our model should be tested on an independent data set.
Our model defines a subgroup of patients at diagnosis of relapse who have only a very small chance of being cured by conventional salvage treatment. Applying our model these patients could avoid the cumulative toxicity of unsuccessful conventional salvage chemotherapy. Moreover, these patients might benefit from early intervention with high-dose chemotherapy because of a potentially lower level of drug resistance compared with patients receiving high-dose chemotherapy at second relapse.
Although pretreatment tumour burden did not enter our multivariate model, it is important to emphasise that MRC criteria and the Indiana University staging system were almost as useful as our model in predicting outcome after salvage treatment in our study population. However, our results showed that patients presenting with poor-risk features according to MRC criteria but being good risk according to our model fared relatively well. Conversely, patients presenting with good-risk features by MRC criteria but designated as poor-risk by our study had a relatively poor prognosis. However, conclusions have to be drawn with caution, since patients with the aforementioned characteristics represented only a small proportion of the entire study population.
In conclusion, we defined a simple prognostic model distinguishing patient groups highly likely and unlikely to be cured by conventional salvage treatment. This model includes response criteria as prognostic variables and might be useful for selecting patients for high-dose chemotherapy at diagnosis of first relapse. However, the validity of our model should be tested on an independent data set, and a clear advantage over prognostic models using only pretreatment characteristics remains to be defined.
